Literature DB >> 7267965

Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients.

A Tarantino, A De Vecchi, G Montagnino, E Imbasciati, M J Mihatsch, H U Zollinger, G B Di Belgiojoso, G Busnach, C Ponticelli.   

Abstract

The mode of presentation of renal disease in 44 patients with essential mixed cryoglobulinaemia (EMC) was: acute renal failure (two patients), acute nephritic syndrome (six patients), nephrotic syndrome (eight patients), proteinuria and/or haematuria (28 patients). Renal biopsy, performed in 35 patients showed proliferative lesions in 33, while only minimal glomerular changes were seen in the remaining two. Immunofluorescence studies showed: IgG (85 per cent), IgA (36 per cent), IgM (90 per cent), C3 (90 per cent), C1q (47 per cent), and C4 (33 per cent) deposits, mainly located in subendothelial position. On electron microscopy, crystalloid structure of deposits and monocyte infiltration of capillary loops were the outstanding feature. The survival rate was 75 per cent at 10 years from the onset of clinical symptoms. Thirty-nine patients were followed for three to 146 months (mean 53.8). Twelve patients died, cardiovascular disease and infection being the commonest cause of death. Thirteen patients showed acute renal failure of acute nephritis syndrome: nine recovered completely, whereas the remaining four died during the acute renal episode. Three patients developed chronic renal failure, but only one period required chronic dialysis. The ominous significance of renal impairment in EMC should therefore be revaluated. The high prevalence of hypertension (28/44 patients) which was refractory to treatment in six, may be important to the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7267965

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  20 in total

Review 1.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  Therapeutic approaches in mixed cryoglobulinemia.

Authors:  D Geltner
Journal:  Springer Semin Immunopathol       Date:  1988

Review 3.  Reappraisal of the clinical expression of mixed cryoglobulinemia.

Authors:  G Montagnino
Journal:  Springer Semin Immunopathol       Date:  1988

4.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 5.  The kidney in mixed cryoglobulinemias.

Authors:  D J Cordonnier; J C Renversez; P Vialtel; E Dechelette
Journal:  Springer Semin Immunopathol       Date:  1987

Review 6.  Renal lesions in dysproteinemias.

Authors:  P Verroust; L Morel-Maroger; J L Preud'Homme
Journal:  Springer Semin Immunopathol       Date:  1982

7.  Acute renal failure with polyarteritis nodosa and multiple myeloma.

Authors:  A J Williams; A C Newland; F P Marsh
Journal:  Postgrad Med J       Date:  1985-05       Impact factor: 2.401

8.  Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis.

Authors:  Anja S Mühlfeld; Stephan Segerer; Kelly Hudkins; Matthew D Carling; Min Wen; Andrew G Farr; Jeffrey V Ravetch; Charles E Alpers
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  Glomerulonephritis in Henoch-Schöenlein purpura without mesangial IgA deposition.

Authors:  C D West; A J McAdams; T R Welch
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

Review 10.  Rituximab as a therapeutic tool in severe mixed cryoglobulinemia.

Authors:  Dario Roccatello; Simone Baldovino; Daniela Rossi; Osvaldo Giachino; Morteza Mansouri; Carla Naretto; Debora Di Simone; Simona Francica; Roberto Cavallo; Mirella Alpa; Franca Napoli; Luigi M Sena
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.